Abstract: The present invention relates to an anti-ICAM-1 antibody or an antigen-binding fragment thereof that specifically binds to ICAM-1, and the use thereof. Specifically, provided are an anti-ICAM-1 antibody or an antigen-binding fragment thereof, a pharmaceutical composition for regulating differentiation and/or function of dendritic cell, and a pharmaceutical composition for preventing and/or treating immune cell-mediated disease, the composition comprising the antibody or the antigen-binding fragment as an active ingredient.
Type:
Grant
Filed:
December 31, 2019
Date of Patent:
April 8, 2025
Assignee:
KUMHO HT, INC.
Inventors:
Yoo Ri Moon, Gil Yong Ji, Sangsoon Yoon, Jung Sik Kim
Abstract: The present invention relates to an antibody or an antigen-binding fragment thereof specifically binding to CD66c which is expressed in myeloid-derived suppressor cell (MDSC) and a use thereof, and specifically to an antibody or an antigen-binding fragment thereof specifically binding to CD66c, a pharmaceutical composition or a diagnosing composition including the same. The anti-CD66c antibody of the present invention can be used usefully for the treatment of various diseases by targeting MDSC which can induce the immunosuppression.
Type:
Grant
Filed:
May 14, 2019
Date of Patent:
September 17, 2024
Assignee:
KUMHO HT, INC.
Inventors:
Soseul Kim, Jeong Won Hong, Gil Yong Ji, Sangsoon Yoon, Hyung-Geun Song
Abstract: The present invention relates to an anti-CD40 antibody binding specifically to CD40 and use thereof and, particularly, provides an anti-CD40 antibody or an antigen-binding fragment thereof, and a pharmaceutical composition comprising the same antibody or fragment as an effective ingredient for prevention and/or treatment of cancer, cancer metastasis, infection, and/or immune deficiency diseases.
Type:
Grant
Filed:
November 10, 2017
Date of Patent:
February 20, 2024
Assignee:
KUMHO HT, INC.
Inventors:
Gil Yong Ji, Kwon Pyo Hong, Eui Sup Lee, Yoo Ri Moon, Sangsoon Yoon
© 2025 Justia
